Pazopanib Hydrochloride
- Product NamePazopanib Hydrochloride
- CAS635702-64-6
- CBNumberCB42495435
- MFC21H24ClN7O2S
- MW473.98
- EINECS619-728-0
- MDL NumberMFCD12546138
- MOL File635702-64-6.mol
- MSDS FileSDS
Chemical Properties
Melting point | >290°C (dec.) |
storage temp. | Hygroscopic, Refrigerator, under inert atmosphere |
solubility | Acetonitrile (Slightly), DMSO (Slightly) |
form | Yellow powder. |
color | White to Off-White |
Stability | Hygroscopic |
NCI Dictionary of Cancer Terms | pazopanib hydrochloride |
FDA UNII | 33Y9ANM545 |
NCI Drug Dictionary | pazopanib hydrochloride |
Pazopanib Hydrochloride Price
Product number | Packaging | Price | Product description | Buy |
---|---|---|---|---|
Sigma-Aldrich SML3076 | 10MG | $86.1 | Pazopanib hydrochloride ≥98% (HPLC) |
Buy |
Sigma-Aldrich SML3076 | 50MG | $348 | Pazopanib hydrochloride ≥98% (HPLC) |
Buy |
ChemScene CS-0126 | 500mg | $420 | PazopanibHydrochloride 99.84% |
Buy |
ApexBio Technology A8347 | 500mg | $480 | PazopanibHydrochloride |
Buy |
ChemScene CS-0126 | 1g | $552 | PazopanibHydrochloride 99.84% |
Buy |
Pazopanib Hydrochloride Chemical Properties,Usage,Production
Description
Pazopanib Hydrochloride is the hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is an oral second-generation multitarget TKI developed by GSK and approved for marketing by the FDA in 2009 and the EMA in 2010. It targets the VEGFR, platelet-derived growth factor receptor, and c-kit, key proteins responsible for tumor growth and survival. It is used to treat patients with advanced RCC and advanced soft tissue sarcoma who have experienced chemotherapy. Pazopanib Hydrochloride has a role as an antineoplastic agent, a vascular endothelial growth factor receptor antagonist, a tyrosine kinase inhibitor, and an angiogenesis-modulating agent.Originator
GlaxoSmithKline (US)Uses
The Hydrochloride salt of Pazopanib (P210925) a oral angiogenesis inhibitor targeting VEGFR and PDGFR.Uses
Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively - See more at: http://www.selleckchem.com/products/Pazopanib-HydUses
Pazopanib Hydrochloride (GW786034, Votrient, Armala) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.Definition
ChEBI: A hydrochloride salt prepared from equimolar amounts of pazopanib and hydrochloric acid. Used for treatment of kidney cancer.Definition
The growth of solid tumors is dependent on angiogenesis, the process wherein new capillaries are formed from existing blood vessels. VEGF is one of the most important inducers of angiogenesis and expressed at high levels by most tumors. Hence, the inhibition of VEGF or its receptor signaling system is an attractive target for cancer therapeutics. The most studied and developed inhibitors are monoclonal antibodies that neutralize VEGF (e.g., bevacizumab), anti-VEGF ribozymes (e.g., angiozyme), and small-molecule VEGFR kinase inhibitors (e.g., sunitinib, sorafenib). Pazopanib is the latest VEGFR kinase inhibitor to reach the market. It is indicated for the oral treatment of advanced RCC. The biological functions of the VEGF family are mediated by activation of three structurally homologous tyrosine kinase receptors, VEGFR-1, VEGFR-2, and VEGFR3. In vitro, pazopanib inhibits VEGFR-1, VEGFR-2, and VEGFR-3 with IC50 values of 10, 30, and 47 nM, respectively. In addition, it inhibits several of the closely related tyrosine receptor kinases, including platelet-derived growth-factor receptor β(PDGFR-β), c-kit, and fibroblast growth factor receptor-1 (FGFR1) with IC50 values of 84, 74, and 140 nM, respectively. In human umbilical vein endothelial cells (HUVEC), pazopanib inhibits VEGF-induced proliferation more potently than basic fibroblast growth factor (bFGF)-stimulated proliferation (IC50 = 21 nM vs. 721 nM) and concentration-dependently inhibits VEGF-induced VEGFR-2 phosphorylation (IC50 = 7 nM). It also potently inhibits angiogenesis in Matrigel plug and corneal micropocket assays. The most common adverse events associated with pazopanib were diarrhea, hypertension, hair depigmentation, nausea, anorexia, and vomiting.brand name
VotrientClinical Use
Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/b, and c-kit that blocks tumor growth and inhibits angiogenesis. It was approved for renal cell carcinoma by the U.S. Food and Drug Administration in 2009 and is marketed under the trade name Votrient by the drug’s manufacturer, GlaxoSmithKline.Side effects
Pazopanib is synthesized in five chemical steps starting from 3-methyl-6-nitroindazole, which is converted to the corresponding 2,3-dimethylindazole analog via N-methylation with trimethyloxonium tetrafluoroborate. Subsequent reduction of the nitro group to the amino group using tin chloride followed by condensation with 2,4dichloropyrimidine yields a chloropyrimidinylaminoindazole intermediate. The final two steps leading up to pazopanib consist of an N-methylation reaction using iodomethane and cesium carbonate followed by condensation with 5-amino-2-methylbenzenesulfonamide.Synthesis
The synthesis of pazopanib begins with methylation of 3-methyl-6- nitroindazole (82) with trimethyl orthoformate in the presence of BF3?¤OEt to give indazole 83 in 65% yield. Reduction of the nitro group was achieved via transfer hydrogenation to give 84 in 97% yield, and this was followed by coupling the aniline with 2,4-dichloropyrimidine in a THF-ethanol mixture at elevated temperature to provide diarylamine 85 in 90% yield. The aniline nitrogen was then methylated using methyl iodide to give 86 in 83% yield prior to coupling with 5-amino-2-methylbenzenesulfonamide (87) and salt formation using an alcoholic solution of HCl to furnish pazopanib hydrochloride (XIV) in 81% yield.target
VEGFR1References
[1] Sodeifian, G. et al. “Solubility of pazopanib hydrochloride (PZH, anticancer drug) in supercritical CO2: Experimental and thermodynamic modeling.” The Journal of Supercritical Fluids 55 1 (2022): 0.[2] “Stability Indicating HPTLC Method Development and Validation for the Estimation of Pazopanib Hydrochloride in Bulk and its Dosage Form.” International Journal of Pharmaceutical Research 18 1 (2020).
[3] K. Kawasaki . “Retrospective Safety Analysis in Advanced Soft Tissue Sarcoma Patients of Pazopanib Hydrochloride.” Annals of Oncology 24 (2013): Page ix38.
[4] Gupta, Amit and Rashmi Dahima. “Application of Simplex Lattice Mixture design and desirability function in the development and Optimization of SEDDS for protein kinase inhibitor-Pazopanib Hydrochloride.” Research Journal of Pharmacy and Technology 83 1 (2023): 0.
Preparation Products And Raw materials
Raw materials
Pazopanib Hydrochloride Supplier
Global(302)Suppliers
Supplier | Tel | Country | ProdList | Advantage | ||
---|---|---|---|---|---|---|
0571-85134551 | info@afinechem.com | CHINA | 15377 | 58 | ||
01056380788-8515; +8618518759099 |
790226113@qq.com | China | 52 | 58 | ||
+86-18752526868 | jennysun@yzqyyykj.com | China | 64 | 58 | ||
010-60279497 | sales01@cooperate-pharm.com | CHINA | 1811 | 55 | ||
+86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21695 | 55 | ||
008657128800458; +8615858145714 |
fandachem@gmail.com | China | 9352 | 55 | ||
+undefined-21-51877795 | ivan@atkchemical.com | China | 32480 | 60 | ||
15380796838 | chloewu@chicopharm.cn | CHINA | 341 | 58 | ||
15950718863 | wang666xt@163.com | CHINA | 295 | 58 | ||
+86-0371-86658258 | sales@coreychem.com | China | 29914 | 58 |
Related articles
Synthesis, Detection and Bioactivity of Pazopanib Hydrochloride
Pazopanib Hydrochloride is an oral angiogenesis inhibitor targeting VEGFR and PDGFR.
Sep 13,2022
Pazopanib Hydrochloride Spectrum
635702-64-6, Pazopanib HydrochlorideRelated Search
- Palonosetron Hydrochloride
- Afatinib
- 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide hydrate
- Cabazitaxel
- Lapatinib ditosylate
- Afatinib dimaleate
- AZD-9291
- Nintedanib Ethanesulfonate Salt
- Pazopanib
- 2,3-DIMETHYL-6-NITRO-2H-INDAZOLE
1of4
PROMPT×
PROMPT
The What'sApp is temporarily not supported in mainland China
The What'sApp is temporarily not supported in mainland China
Cancel
Determine